



# Hepatitis C Virus Incidence in the Amsterdam Cohort Study among Men who have Sex with Men; 1984-2011





Joost W. Vanhommerig<sup>1,2,\*</sup>, Ineke G. Stolte<sup>1</sup>, Femke A.E. Lambers<sup>1</sup>, Ronald B. Geskus<sup>1,3</sup>, Thijs J.W. van de Laar<sup>4</sup>, Sylvia M. Bruisten<sup>1</sup>, Janke Schinkel<sup>2</sup>, Maria Prins<sup>1,5</sup>

1 Department of Infectious Diseases, Public Health Service, Amsterdam, the Netherlands; 2 Department of Medical Microbiology, Academic Medical Center, Amsterdam, the Netherlands; 3 Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, the Netherlands; 4 Department of Blood-borne Infections, Sanquin Blood Supply Foundation, Amsterdam, the Netherlands; 5 Department of Infectious diseases and Immunology Amsterdam (CINIMA), Academic Medical Center, Amsterdam, the Netherlands; \* contact: <a href="mailto:juanhommerig@ggd.amsterdam.nl">juanhommerig@ggd.amsterdam.nl</a>

**Objectives Discussion** 

Since 2000, an epidemic of HCV emerged among HIV-infected men who have sex with men (MSM). An increase in HCV incidence was observed earlier in the Amsterdam Cohort Studies (ACS), between 2000 and 2003. Data collected during bi-annual surveys at the Amsterdam STI clinic, suggested that the HCV epidemic among HIV-infected MSM in Amsterdam has levelled off in recent years. We updated our previous ACS analysis to examine recent changes.

Among HIV-infected MSM, HCV incidence rates increased significantly between 2000 and 2005. Thereafter, incidence seems to have stabilized at around 12/1,000 PYs. No incident HCV infections were found among HIV-uninfected MSM, despite more than 10,000 years of follow-up.

Our findings are in line with findings from the Amsterdam STI clinic, and may be explained by an increase in HCV testing and treatment uptake, risk reduction, or a saturation-effect among MSM at highest risk for HCV infection.

## **Background**

- Since 2000, the incidence of HCV infection among HIV-positive MSM in high-income countries has increased substantially; among HIV-negative MSM, the prevalence of HCV remained low.<sup>1</sup>
- Previous analysis of ACS data showed that the HCV incidence among HIV-positive MSM increased from 0.78 per 1,000 person-years (PYs) before 2000, to 8.74 per 1,000 PYs in 2000-2003.<sup>2</sup>
- Data from the Amsterdam STI clinic showed a non-significant decline in prevalence of HCV among HIV-positive MSM after 2008.<sup>3</sup>

### Methods

### **Participants**

- HIV-negative and HIV-positive MSM with ≥2 study visits in the ACS between October 1984 and January 2012 were included.
- To update HCV status, linkage with clinical and laboratory databases took place from the Dutch HIV Monitoring Foundation, AMC, and Medical Center Jan van Goyen.
- HIV-positive MSM were the tested for HCV antibodies at the last visit before 2012 if no negative HCV test result was available after 2008.
- HIV-negative MSM were tested for HCV antibodies at their first 6-monthly ACS visit after STI screening was introduced in October 2008.

### Statistics

- Risk factors for prevalent HCV were studied using univariate logistic regression models.
- Incidence rates were calculated per year, trends over time were analyzed using Poisson regression.
- Risk factors for incident HCV were studied using Poisson regression; variables subject to change were treated as time-updated covariates.


### Laboratory methods


 HCV antibody tests were performed by AxSYM HCV 3.0 (Abbott); confirmation by immunoblot (Ortho-Clinical Diagnostics) and by HCV-RNA (TMA; Siemens).

# **Figure 1:** Observed and fitted HCV incidence rate per 1,000 PYs of follow-up.

- A) HCV incidence rate among 761 HIV-positive MSM participating in the ACS, 1984-2011.
- B) HCV incidence rate by age, in 2008.

Restricted cubic splines allowed for smoothly varying trends in the modeled incidence. The shaded area is the 95% confidence interval.





### Results

### General characteristics

■ 2,457 MSM were enrolled In the ACS between 1984 and 2012; 2,104 MSM had ≥2 study visits; the total follow-up was 17,310 PYs. At study entry, 539 were HIV-infected and 222 seroconverted during follow-up.

### Prevalent HCV infection

- 24/2,104 (1.1%) were HCV-positive at the first study visit. This was associated with history (Hx) of injecting drug use (OR: 84.6; P<.001), HIV-coinfection (OR: 3.12; P=.006); the effect of older age was borderline significant (OR per 10y increment: 1.52; P=.066).</p>
- Hx of blood transfusion, Hx of syphilis, number of sex partners ever, or in the 5
  years preceding study entry, were not significantly associated with prevalent HCV.

### Incident HCV infection

- 29 incident HCV infections were documented among 2,080 MSM who were HCV-negative at study entry; all incident cases were HIV-infected (Figure 1A).
- Incident HCV was associated with younger age (RR for age 50 vs. age 35: 0.31, 95%
   CI: 0.11-0.89; P=.041; Figure 1B).
- CD4 count, nadir CD4 count before infection, HIV viral load, and use of cART, were not significantly associated with incident HCV infection.
- A significant increase in HCV incidence was observed after 2000:

IR<sub>2005</sub> vs IR<sub>2000</sub> -- IRR: 3.41, 95% CI: 1.58-7.34; *P*=.002

After 2005, HCV incidence stabilized at around 12/1,000 PYs:

IR<sub>2010</sub> vs IR<sub>2005</sub> -- IRR: 0.94, 95% CI: 0.38-2.36; *P*=.906



### References

<sup>1</sup> Bradshaw D et al. Sexually transmitted hepatitis C infection: the new epidemic in MSM? Curr Opin Infect Dis 2013; <sup>2</sup>Van de Laar et al. Increase in HCV incidence among men who have sex with men in Amsterdom most likely caused by sexual transmission. I Infect Dis 2007; <sup>3</sup> Urbanus et al. Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection (infect 1945–2010). AIDS 2014.